We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Federal Trade Commission (FTC) has requested that both Roche and Spark Therapeutics submit additional information and documentary material regarding their proposed merger agreement.
CPhI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.